The world of new biotech medications is one of approvals and big money. Put the two together and a large reward may be at the end of the rainbow. A misstep, anywhere along the yellow brick road, and the wicked witch may be waiting.
Immunosyn Corporation, Inc., a biotechnology company oriented toward developing new products directed at auto immune disorders, is currently proceeding with trial start-up of its world rights granted SF-1019 product. The SF-1019 product is designed to address issues such as: diabetes, diabetic neuropathy, multiple sclerosis and other numerous neurological disorders.
In more traditional drug trial schedules, the company might be thought to be at the very beginning of the approvals process. This, however, is not the case. Particularly in Europe, the company has filed for orphan drug status. If this status is granted, the identified drug receives a fast track status toward approval. Currently, European status of this application appears positive. Ongoing approvals are currently active in several countries including the United States. In this particular market, status as an orphan drug may be a bit less certain. Over an extended period of time, however, it is more likely.
Generally, the company appears to be a one drug biotechnology company with potentially lucrative markets that are numerous. Success of the company is likely based on approvals, although the up-side could be large if development, approvals and overall success of SF-1019 is achieved. From all appearances, and a fairly generous and positive outlook from the company, regulatory and financial issues are on track. From an outside perspective the company is a fledgling biotechnology company with an experienced management team and, apparently, deep pockets.
Let us hear your thoughts below: